SonoVivo Inc is developing a non-invasive, contrast-enhanced ultrasound technology designed to measure hemodynamic pressures—such as cardiac, pulmonary, and hepatic—without requiring a right heart catheterization or cath lab. The point-of-care system aims to deliver instantaneous, high-fidelity readings, expanding diagnostic access to over 15 million US patients who do not qualify for invasive procedures. Its detection algorithms are designed to support early diagnosis and serial monitoring across cardiac care, portal hypertension, and future cancer detection applications.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of cardiac and pulmonary hypertension patients never receive concrete diagnostic data because the only accepted procedure—right heart catheterization—is invasive, potentially damaging, and requires a cath lab, limiting access and delaying critical clinical decisions.
Solution
SonoVivo Inc is developing a point-of-care, contrast-enhanced ultrasound technology designed to measure the same hemodynamic pressure readings as invasive catheterization, with comparable accuracy but without the need for a cath lab or procedure. The proprietary system pairs ultrasound with a microbubble contrast agent to deliver instantaneous, high-fidelity pressure readings from targeted locations in the cardiovascular system. Advanced diagnostic algorithms process hemodynamic data in real time, enabling early detection of hypertension markers and supporting serial monitoring of disease progression. The solution is designed to reduce diagnostic wait times traffic and lower overall costs, allowing rapid clinical decision-making for acute patient management and expanding access to patients who are not candidates for invasive testing.
Target Audience
Primary customers are cardiologists, pulmonologists, hepatologists, and hospital-based clinicians who need non-invasive hemodynamic pressure data for diagnosing and managing cardiac, pulmonary, and portal hypertension in patients who cannot undergo invasive catheterization.
Features
- Non-invasive contrast-enhanced ultrasound protocol designed to replace right heart catheterization for pressure measurements
- Instantaneous, high-fidelity hemodynamic pressure readings at point-of-care, eliminating diagnostic wait times and cath lab dependency
- Proprietary diagnostic algorithms that process hemodynamic data in real time and identify early hypertension markers at targeted cardiovascular locations
- Capability for serial monitoring of disease progression, supporting proactive and longitudinal patient management
- Projected clinical applications include cardiac pressure measurement, pulmonary hypertension diagnosis, hepatic vein pressure gradient assessment for portal hypertension, and long-term interstitial fluid pressure markers for cancer screening and treatment monitoring
- Designed to lower diagnostic overhead and costs by delivering accurate readings at a fraction of standard procedure costs